董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andrew Allen | 男 | Director | 56 | 8.66万美元 | 未持股 | 2022-08-29 |
| Neil Gibson | 男 | Director | 66 | 9.25万美元 | 未持股 | 2022-08-29 |
| Garry Menzel | 男 | Director,President and Chief Executive Officer | 58 | 190.45万美元 | 未持股 | 2022-08-29 |
| Axel Hoos | 男 | Director | 52 | 7.81万美元 | 未持股 | 2022-08-29 |
| Priti Hegde | 女 | Director | 50 | 29.74万美元 | 未持股 | 2022-08-29 |
| Shawn C. Tomasello | 女 | Director | 63 | 40.54万美元 | 未持股 | 2022-08-29 |
| Stephen W. Webster | 男 | Director and Chairman of the Board | 61 | 8.91万美元 | 未持股 | 2022-08-29 |
| Ansbert Gadicke | 男 | Director | 64 | 未披露 | 未持股 | 2022-08-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Alfonso Quintas Cardama | 男 | Chief Medical Officer | 51 | 103.91万美元 | 未持股 | 2022-08-29 |
| Garry Menzel | 男 | Director,President and Chief Executive Officer | 58 | 190.45万美元 | 未持股 | 2022-08-29 |
| Angela Justice | 女 | Chief People Officer | 50 | 未披露 | 未持股 | 2022-08-29 |
| Peter Olagunju | 男 | Chief Technical Officer | 44 | 273.62万美元 | 未持股 | 2022-08-29 |
| Rosemary Harrison | 女 | Chief Business and Strategy Officer | 39 | 未披露 | 未持股 | 2022-08-29 |
| Stephen W. Webster | 男 | Director and Chairman of the Board | 61 | 8.91万美元 | 未持股 | 2022-08-29 |
| Eric Sullivan | 男 | Chief Financial Officer | 43 | 未披露 | 未持股 | 2022-08-29 |
董事简历
中英对照 | 中文 | 英文- Andrew Allen
-
Andrew Allen于2018年12月加入我们的董事会。艾伦博士是GritstoneOncology，Inc.的联合创始人，自2015年8月起担任其总裁兼首席执行官。2009年4月至2015年7月，Allen博士共同创立了ClovisOncology，Inc.，该公司是一家公共医药开发公司，并担任其临床和临床前开发执行Vice President兼首席医疗官。此前，他曾担任Pharmion Corporation的首席医疗官（从2006年到2008年）。此前，艾伦博士曾在Chiron Corporation和雅培公司担任临床开发领导职务，并在麦肯锡公司（McKinsey&Company）工作，在那里他为生命科学公司提供战略问题方面的建议。他目前任职于GritstoneOncology，Inc.、Epizyme，Inc.、SierraOncology，Inc.和Revisope Oncology，Inc.的董事会。艾伦博士曾于2015年11月至2017年12月被吉利德科学公司收购期间担任私营生物技术公司Cell Design Labs的董事会成员。Allen博士在牛津大学（Oxford University）获得医学资格，并在伦敦帝国理工学院（Imperial College of Science，Technology and Medicine）获得免疫学博士学位。
Andrew Allen joined Tcr2 Therapeutics Inc. Board of Directors in December 2018. Dr. Allen is a co-founder of Gritstone Oncology, Inc., and has served as its President and Chief Executive Officer since August 2015. Dr. Allen previously co-founded Clovis Oncology, Inc., a public pharmaceutical development company, and served as its executive vice president of clinical and preclinical development and chief medical officer from April 2009 to July 2015. Prior to that, he was chief medical officer at Pharmion Corporation from 2006 to 2008. Previously, Dr. Allen served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey & Company, where he advised life science companies on strategic issues. He currently serves on the board of directors of Gritstone Oncology, Inc., Sierra Oncology, Inc., Revitope Oncology, Inc. and Verge Genomics, Inc. Dr. Allen previously served on the board of directors for Epizyme, Inc. from 2014 until 2021 and Cell Design Labs, a private biotechnology company, from November 2015 until its acquisition by Gilead Sciences, Inc. in December 2017. Dr. Allen qualified in medicine at Oxford University and received a Ph.D. in immunology from Imperial College of Science, Technology and Medicine in London. - Andrew Allen于2018年12月加入我们的董事会。艾伦博士是GritstoneOncology，Inc.的联合创始人，自2015年8月起担任其总裁兼首席执行官。2009年4月至2015年7月，Allen博士共同创立了ClovisOncology，Inc.，该公司是一家公共医药开发公司，并担任其临床和临床前开发执行Vice President兼首席医疗官。此前，他曾担任Pharmion Corporation的首席医疗官（从2006年到2008年）。此前，艾伦博士曾在Chiron Corporation和雅培公司担任临床开发领导职务，并在麦肯锡公司（McKinsey&Company）工作，在那里他为生命科学公司提供战略问题方面的建议。他目前任职于GritstoneOncology，Inc.、Epizyme，Inc.、SierraOncology，Inc.和Revisope Oncology，Inc.的董事会。艾伦博士曾于2015年11月至2017年12月被吉利德科学公司收购期间担任私营生物技术公司Cell Design Labs的董事会成员。Allen博士在牛津大学（Oxford University）获得医学资格，并在伦敦帝国理工学院（Imperial College of Science，Technology and Medicine）获得免疫学博士学位。
- Andrew Allen joined Tcr2 Therapeutics Inc. Board of Directors in December 2018. Dr. Allen is a co-founder of Gritstone Oncology, Inc., and has served as its President and Chief Executive Officer since August 2015. Dr. Allen previously co-founded Clovis Oncology, Inc., a public pharmaceutical development company, and served as its executive vice president of clinical and preclinical development and chief medical officer from April 2009 to July 2015. Prior to that, he was chief medical officer at Pharmion Corporation from 2006 to 2008. Previously, Dr. Allen served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey & Company, where he advised life science companies on strategic issues. He currently serves on the board of directors of Gritstone Oncology, Inc., Sierra Oncology, Inc., Revitope Oncology, Inc. and Verge Genomics, Inc. Dr. Allen previously served on the board of directors for Epizyme, Inc. from 2014 until 2021 and Cell Design Labs, a private biotechnology company, from November 2015 until its acquisition by Gilead Sciences, Inc. in December 2017. Dr. Allen qualified in medicine at Oxford University and received a Ph.D. in immunology from Imperial College of Science, Technology and Medicine in London.
- Neil Gibson
-
Neil Gibson自2020年6月起担任董事会成员，自2021年3月起担任首席独立董事。吉布森博士自2017年以来一直担任COI Pharmaceuticals，Inc.公司Adanate的总裁兼首席执行官。吉布森博士曾在生物技术和制药行业担任多个高级职位，包括2017年至2020年担任PDI Therapeutics的总裁兼首席执行官，2015年至2016年担任Bioatla，Inc.高级副总裁，2011年至2015年担任Regulus Therapeutics的首席科学官。吉布森博士自2017年以来一直担任TCR2和Causeway Therapeutics的董事会成员，此前曾于2016年至2019年担任Cytosen Therapeutics的董事会成员。吉布森博士获得了理学学士学位。the University of Strathclyde的药学博士学位和the University of Aston的博士学位。
Neil Gibson joined Tcr2 Therapeutics Inc. Board of Directors in February 2018. Dr. Gibson served as Senior Vice President to COI Pharmaceuticals, Inc., an accelerator company focused on the creation and development of unique drug discover companies, from 2016 to 2021. As SVP for COI, Dr. Gibson served as President and CEO of Adanate from 2017 to 2021 and President and CEO of PDI Therapeutics from 2017 to 2020. From 2015 to 2016 Dr. Gibson served as Senior Vice President and Chief Development Officer to BioAtla LLC. From 2011 to 2015 he served as Chief Scientific Officer of Regulus Therapeutics Inc., and from 2007 to 2011 he was Chief Scientific Officer of Pfizer Oncology based in La Jolla, CA. Dr. Gibson is a member of the board of directors of Shattuck Labs, Inc. and Instill Bio, Inc. Dr. Gibson received his Ph.D. from the University of Aston and his B.Sc. from the University of Strathclyde. - Neil Gibson自2020年6月起担任董事会成员，自2021年3月起担任首席独立董事。吉布森博士自2017年以来一直担任COI Pharmaceuticals，Inc.公司Adanate的总裁兼首席执行官。吉布森博士曾在生物技术和制药行业担任多个高级职位，包括2017年至2020年担任PDI Therapeutics的总裁兼首席执行官，2015年至2016年担任Bioatla，Inc.高级副总裁，2011年至2015年担任Regulus Therapeutics的首席科学官。吉布森博士自2017年以来一直担任TCR2和Causeway Therapeutics的董事会成员，此前曾于2016年至2019年担任Cytosen Therapeutics的董事会成员。吉布森博士获得了理学学士学位。the University of Strathclyde的药学博士学位和the University of Aston的博士学位。
- Neil Gibson joined Tcr2 Therapeutics Inc. Board of Directors in February 2018. Dr. Gibson served as Senior Vice President to COI Pharmaceuticals, Inc., an accelerator company focused on the creation and development of unique drug discover companies, from 2016 to 2021. As SVP for COI, Dr. Gibson served as President and CEO of Adanate from 2017 to 2021 and President and CEO of PDI Therapeutics from 2017 to 2020. From 2015 to 2016 Dr. Gibson served as Senior Vice President and Chief Development Officer to BioAtla LLC. From 2011 to 2015 he served as Chief Scientific Officer of Regulus Therapeutics Inc., and from 2007 to 2011 he was Chief Scientific Officer of Pfizer Oncology based in La Jolla, CA. Dr. Gibson is a member of the board of directors of Shattuck Labs, Inc. and Instill Bio, Inc. Dr. Gibson received his Ph.D. from the University of Aston and his B.Sc. from the University of Strathclyde.
- Garry Menzel
-
Garry Menzel于2016年加入我们公司，担任董事兼首席执行官。Menzel博士自2014年以来还担任肿瘤公司Black Diamond Therapeutics Inc.的董事会和审计委员会主席。此前，孟泽尔博士曾于2015年至2016年担任Axcella HealthInc.首席战略官，2013年至2015年担任达维塔梦百合Partners Inc.首席财务官，2008年至2013年担任Regulus TherapeuticsInc.首席运营官。Menzel博士还分别于1994年至2004年和2004年至2008年在高盛公司（Goldman Sachs&Co.LLC）和Credit Suisse Group Ag公司（McKinsey）担任生物技术实践的全球领导职务。此外，他还是贝恩咨询公司（Bain&Company）的顾问，也是SmithKline Beecham plc（现为GlaxoSmithKline plc）的研究助理。Menzel博士在剑桥大学（University of Cambridge）获得博士学位，在那里他研究免疫细胞中癌基因的调控，并在斯坦福大学商学院（Stanford University Graduate School of Business）获得工商管理硕士学位。
Garry Menzel joined Tcr2 Therapeutics Inc. company in 2016 as a director and Chief Executive Officer. Dr. Menzel has also served on the Board of Directors and chairman of the audit committee of the oncology company Black Diamond Therapeutics Inc. since 2014 and has served on the Board of Directors of Stoke Therapeutics Inc. since 2020. Previously, Dr. Menzel was the Chief Strategy Officer at Axcella Health Inc. from 2015 to 2016 the Chief Financial Officer at DaVita Healthcare Partners Inc. from 2013 to 2015 and the Chief Operating Officer at Regulus Therapeutics Inc. from 2008 to 2013. Dr. Menzel also had global leadership roles in running the biotechnology practices at Goldman Sachs & Co. LLC from 1994 to 2004 and Credit Suisse Group AG from 2004 to 2008. In addition, he was a consultant with Bain & Company and was a research assistant at SmithKline Beecham PLC now GlaxoSmithKline PLC. Dr. Menzel received his Ph.D. from the University of Cambridge, where he studied the regulation of oncogenes in immune cells, and his M.B.A. from the Stanford University Graduate School of Business. - Garry Menzel于2016年加入我们公司，担任董事兼首席执行官。Menzel博士自2014年以来还担任肿瘤公司Black Diamond Therapeutics Inc.的董事会和审计委员会主席。此前，孟泽尔博士曾于2015年至2016年担任Axcella HealthInc.首席战略官，2013年至2015年担任达维塔梦百合Partners Inc.首席财务官，2008年至2013年担任Regulus TherapeuticsInc.首席运营官。Menzel博士还分别于1994年至2004年和2004年至2008年在高盛公司（Goldman Sachs&Co.LLC）和Credit Suisse Group Ag公司（McKinsey）担任生物技术实践的全球领导职务。此外，他还是贝恩咨询公司（Bain&Company）的顾问，也是SmithKline Beecham plc（现为GlaxoSmithKline plc）的研究助理。Menzel博士在剑桥大学（University of Cambridge）获得博士学位，在那里他研究免疫细胞中癌基因的调控，并在斯坦福大学商学院（Stanford University Graduate School of Business）获得工商管理硕士学位。
- Garry Menzel joined Tcr2 Therapeutics Inc. company in 2016 as a director and Chief Executive Officer. Dr. Menzel has also served on the Board of Directors and chairman of the audit committee of the oncology company Black Diamond Therapeutics Inc. since 2014 and has served on the Board of Directors of Stoke Therapeutics Inc. since 2020. Previously, Dr. Menzel was the Chief Strategy Officer at Axcella Health Inc. from 2015 to 2016 the Chief Financial Officer at DaVita Healthcare Partners Inc. from 2013 to 2015 and the Chief Operating Officer at Regulus Therapeutics Inc. from 2008 to 2013. Dr. Menzel also had global leadership roles in running the biotechnology practices at Goldman Sachs & Co. LLC from 1994 to 2004 and Credit Suisse Group AG from 2004 to 2008. In addition, he was a consultant with Bain & Company and was a research assistant at SmithKline Beecham PLC now GlaxoSmithKline PLC. Dr. Menzel received his Ph.D. from the University of Cambridge, where he studied the regulation of oncogenes in immune cells, and his M.B.A. from the Stanford University Graduate School of Business.
- Axel Hoos
-
AxelHoos是葛兰素史克制药公司（GSK）的高级副总裁，研发治理主席和肿瘤治疗领域主管。作为研发治理主席，他监管技术和资金审查委员会。作为治疗领域主管，他负责肿瘤业务，包括免疫肿瘤学、表观遗传学、细胞和基因治疗和合成致死性的四个重点领域的发现和开发。他也曾负责领导业务发展组合扩张，包括收购Tesaro公司，以及Adaptimmune公司、Lyell公司和Immatics公司的细胞和基因治疗许可协议。Hoos博士还担任萨宾疫苗研究所（Sabin Vaccine Institute）的董事会主席，是Imugene的联合创始人兼董事，Imugene是一家生物技术公司，癌症免疫治疗财团的联合董事和癌症研究所的科学顾问委员会成员。任职GSK公司之前，他曾担任Bristol-Myers Squibb公司的免疫学/肿瘤学全球医学主管，在那里他曾开发Yervoy公司（ipilimumab公司），这是免疫肿瘤学的第一个检查点抑制剂药物。iPilimumab的科学机制的发现于2018年被授予James Allison博士的诺贝尔生理学或医学奖。Hoos博士也是Agenus Bio的临床开发高级总监。Hoos博士拥有Ruprecht-Karls-University的医学博士学位和德国癌症研究中心（DKFZ）的分子肿瘤学博士学位。他在慕尼黑技术大学（Technical University）和纽约市纪念斯隆-凯特琳癌症中心（Memorial Sloan-Kettering Cancer Center）接受外科培训（在那里他也学习分子病理学和肿瘤免疫学）。他是哈佛商学院（Harvard Business School）领导力发展项目的校友。
Axel Hoos joined Tcr2 Therapeutics Inc. Board of Directors in April 2020. Dr. Hoos has served as Chief Executive Officer and a member of the board of directors of Scorpion Therapeutics, Inc. since 2021. Dr. Hoos also serves as chairman of the Board of Trustees of the Sabin Vaccine Institute, is Co-founder and director on the board of Imugene, a biotech company, Co-director of the Cancer Immunotherapy Consortium and Scientific Advisory Board Member of the Cancer Research Institute. Prior to Scorpion Therapeutics, Dr. Hoos was Senior Vice President, R&D Governance Chair, and Therapeutic Area Head for Oncology at GlaxoSmithKline Pharmaceuticals GSK. He served as Therapeutic Area Head at GSK from 2012 to 2021 and was responsible for the Oncology business including discovery and development with the four focus areas of immuno-oncology, epigenetics, cell & gene therapy and synthetic lethality. He served as R&D Governance Chair at GSK from 2018 to 2021 where he oversaw technical and funding review committees. Prior to GSK, Dr. Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb where he developed Yervoy (Ipilimumab) which was the first checkpoint inhibitor drug in immuno-oncology. Dr. Hoos was also Senior Director of Clinical Development at Agenus Bio. Dr. Hoos holds an MD from Ruprecht-Karls-University and a PhD in molecular oncology from the German Cancer Research Center (DKFZ). He trained in surgery at the Technical University in Munich and at Memorial Sloan-Kettering Cancer Center in New York City (where he also studied molecular pathology and tumor immunology). He is an alumnus of the Program for Leadership Development at Harvard Business School. - AxelHoos是葛兰素史克制药公司（GSK）的高级副总裁，研发治理主席和肿瘤治疗领域主管。作为研发治理主席，他监管技术和资金审查委员会。作为治疗领域主管，他负责肿瘤业务，包括免疫肿瘤学、表观遗传学、细胞和基因治疗和合成致死性的四个重点领域的发现和开发。他也曾负责领导业务发展组合扩张，包括收购Tesaro公司，以及Adaptimmune公司、Lyell公司和Immatics公司的细胞和基因治疗许可协议。Hoos博士还担任萨宾疫苗研究所（Sabin Vaccine Institute）的董事会主席，是Imugene的联合创始人兼董事，Imugene是一家生物技术公司，癌症免疫治疗财团的联合董事和癌症研究所的科学顾问委员会成员。任职GSK公司之前，他曾担任Bristol-Myers Squibb公司的免疫学/肿瘤学全球医学主管，在那里他曾开发Yervoy公司（ipilimumab公司），这是免疫肿瘤学的第一个检查点抑制剂药物。iPilimumab的科学机制的发现于2018年被授予James Allison博士的诺贝尔生理学或医学奖。Hoos博士也是Agenus Bio的临床开发高级总监。Hoos博士拥有Ruprecht-Karls-University的医学博士学位和德国癌症研究中心（DKFZ）的分子肿瘤学博士学位。他在慕尼黑技术大学（Technical University）和纽约市纪念斯隆-凯特琳癌症中心（Memorial Sloan-Kettering Cancer Center）接受外科培训（在那里他也学习分子病理学和肿瘤免疫学）。他是哈佛商学院（Harvard Business School）领导力发展项目的校友。
- Axel Hoos joined Tcr2 Therapeutics Inc. Board of Directors in April 2020. Dr. Hoos has served as Chief Executive Officer and a member of the board of directors of Scorpion Therapeutics, Inc. since 2021. Dr. Hoos also serves as chairman of the Board of Trustees of the Sabin Vaccine Institute, is Co-founder and director on the board of Imugene, a biotech company, Co-director of the Cancer Immunotherapy Consortium and Scientific Advisory Board Member of the Cancer Research Institute. Prior to Scorpion Therapeutics, Dr. Hoos was Senior Vice President, R&D Governance Chair, and Therapeutic Area Head for Oncology at GlaxoSmithKline Pharmaceuticals GSK. He served as Therapeutic Area Head at GSK from 2012 to 2021 and was responsible for the Oncology business including discovery and development with the four focus areas of immuno-oncology, epigenetics, cell & gene therapy and synthetic lethality. He served as R&D Governance Chair at GSK from 2018 to 2021 where he oversaw technical and funding review committees. Prior to GSK, Dr. Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb where he developed Yervoy (Ipilimumab) which was the first checkpoint inhibitor drug in immuno-oncology. Dr. Hoos was also Senior Director of Clinical Development at Agenus Bio. Dr. Hoos holds an MD from Ruprecht-Karls-University and a PhD in molecular oncology from the German Cancer Research Center (DKFZ). He trained in surgery at the Technical University in Munich and at Memorial Sloan-Kettering Cancer Center in New York City (where he also studied molecular pathology and tumor immunology). He is an alumnus of the Program for Leadership Development at Harvard Business School.
- Priti Hegde
-
Priti Hegde于2021年8月加入我们的董事会。Hegde博士自2019年8月起担任FoundationMedicine，Inc.的首席科学官。此前，2007年至2019年，Hegde博士在Genentech，Inc.担任越来越多的职务，包括担任肿瘤生物标志物开发高级董事和首席科学家。在加入Genentech，Inc.之前，Hegde博士是GlaxoSmithKline plc疾病和生物标志物转录组学的经理。Hedge博士完成了她在基因组研究所的博士后研究，拥有Suny Buffalo的生化药理学博士学位，以及印度孟买大学的药学学士学位。
Priti Hegde joined Tcr2 Therapeutics Inc. Board of Directors in August 2021. Dr. Hegde has served as Chief Scientific Officer of Foundation Medicine Inc. since 2019 where she oversees clinical product development, cancer genomics, regulatory and early stage research to advance their leading comprehensive genomic profiling portfolio. Previously, Dr. Hegde held roles of increasing responsibility at Genentech for 12 years, including as Senior Director in Oncology Biomarker Development from 2016 to 2019 during which she established and led the biomarker group accountable for translational science strategies in cancer immunotherapy and was responsible for clinical translation strategies for more than 18 therapeutic programs in over 100 Phase I-III global clinical trials. Dr. Hegde was also instrumental in the approvals for Tecentriq® atezolizumab, a PD-L1 immunotherapy, in both the United States and European Union, as well as its forthcoming diagnostic filings. Prior to joining Genentech, Dr. Hegde was the manager of disease and biomarker transcriptomics at GlaxoSmithKline. She completed her post-doctoral fellowship at The Institute for Genomic Research and holds a Ph.D. in Biochemical Pharmacology from SUNY Buffalo, as well as a B. Pharmacy degree from Mumbai University, India. - Priti Hegde于2021年8月加入我们的董事会。Hegde博士自2019年8月起担任FoundationMedicine，Inc.的首席科学官。此前，2007年至2019年，Hegde博士在Genentech，Inc.担任越来越多的职务，包括担任肿瘤生物标志物开发高级董事和首席科学家。在加入Genentech，Inc.之前，Hegde博士是GlaxoSmithKline plc疾病和生物标志物转录组学的经理。Hedge博士完成了她在基因组研究所的博士后研究，拥有Suny Buffalo的生化药理学博士学位，以及印度孟买大学的药学学士学位。
- Priti Hegde joined Tcr2 Therapeutics Inc. Board of Directors in August 2021. Dr. Hegde has served as Chief Scientific Officer of Foundation Medicine Inc. since 2019 where she oversees clinical product development, cancer genomics, regulatory and early stage research to advance their leading comprehensive genomic profiling portfolio. Previously, Dr. Hegde held roles of increasing responsibility at Genentech for 12 years, including as Senior Director in Oncology Biomarker Development from 2016 to 2019 during which she established and led the biomarker group accountable for translational science strategies in cancer immunotherapy and was responsible for clinical translation strategies for more than 18 therapeutic programs in over 100 Phase I-III global clinical trials. Dr. Hegde was also instrumental in the approvals for Tecentriq® atezolizumab, a PD-L1 immunotherapy, in both the United States and European Union, as well as its forthcoming diagnostic filings. Prior to joining Genentech, Dr. Hegde was the manager of disease and biomarker transcriptomics at GlaxoSmithKline. She completed her post-doctoral fellowship at The Institute for Genomic Research and holds a Ph.D. in Biochemical Pharmacology from SUNY Buffalo, as well as a B. Pharmacy degree from Mumbai University, India.
- Shawn C. Tomasello
-
Shawn C. Tomasello自2019年6月起担任Gamida Cell Ltd.董事会成员。Tomasello女士于2015年至2018年担任Kite Pharma, Inc.（一家从事癌症免疫治疗产品开发的公司）的首席商务官。加入Kite Pharma （Gilead Sciences, Inc.的一部分）之前（2014年至2015年），Tomasello女士担任Pharmacyclics Inc.（纳斯达克代码：PCYC）的首席商务官，Pharmacyclics Inc公司被Abbvie, Inc.收购。从2005年4月到2014年8月，Tomasello女士受雇于Celgene Corporation（纳斯达克代码：CELG），最初担任销售和培训副总裁，然后担任美洲血液学和肿瘤学总裁，在那里她负责商业组织的所有方面，包括11个适应症的多个品牌。加入Celgene Corporation之前，Tomasello女士从1989年到2005年在Genentech, Inc.（前纽约证券交易所股票代码：DNA）工作。从2003年初到2005年4月，她在Genentech的最后一个职位是血液学特许经营公司（Rituxan）的全国总监。Tomasello女士是Urogen Pharma Ltd.（纳斯达克股票代码：URGN）、Mesoblast Limited （ASX股票代码：MSB）、Centrexion Therapeutics、TCR2和4DMT的董事会成员。Tomasello女士在辛辛那提大学（University of Cincinnati）获得营销学士学位，在肯塔基州默里州立大学（Murray State University）获得工商管理硕士学位。
Shawn C. Tomasello,has served on the Board since June 2019.From 2015 to 2018, Ms. Tomasello as the Chief Commercial Officer of Kite Pharma. Prior to joining Kite Pharma, from 2014 to 2015, Ms. Tomasello served as the Chief Commercial Officer of Pharmacyclics Inc. (Nasdaq: PCYC), a pharmaceutical manufacturer acquired by Abbvie, Inc. (NYSE: ABBV). From April 2005 to August 2014, Ms. Tomasello was employed at Celgene Corporation, most recently as President of the Americas, Hematology and Oncology, where she was responsible for all aspects of the commercial organization encompassing multiple brands spanning 11 indications. Ms. Tomasello serves on the board of directors of Cabaletta Bio (Nasdaq: CABA), 4D Molecular Therapeutics (Nasdaq: FDMT) and AlloVir, Inc. (Nasdaq: ALVR). Ms. Tomasello earned her B.S. in Marketing from the University of Cincinnati and her M.B.A. from Murray State University, Kentucky. - Shawn C. Tomasello自2019年6月起担任Gamida Cell Ltd.董事会成员。Tomasello女士于2015年至2018年担任Kite Pharma, Inc.（一家从事癌症免疫治疗产品开发的公司）的首席商务官。加入Kite Pharma （Gilead Sciences, Inc.的一部分）之前（2014年至2015年），Tomasello女士担任Pharmacyclics Inc.（纳斯达克代码：PCYC）的首席商务官，Pharmacyclics Inc公司被Abbvie, Inc.收购。从2005年4月到2014年8月，Tomasello女士受雇于Celgene Corporation（纳斯达克代码：CELG），最初担任销售和培训副总裁，然后担任美洲血液学和肿瘤学总裁，在那里她负责商业组织的所有方面，包括11个适应症的多个品牌。加入Celgene Corporation之前，Tomasello女士从1989年到2005年在Genentech, Inc.（前纽约证券交易所股票代码：DNA）工作。从2003年初到2005年4月，她在Genentech的最后一个职位是血液学特许经营公司（Rituxan）的全国总监。Tomasello女士是Urogen Pharma Ltd.（纳斯达克股票代码：URGN）、Mesoblast Limited （ASX股票代码：MSB）、Centrexion Therapeutics、TCR2和4DMT的董事会成员。Tomasello女士在辛辛那提大学（University of Cincinnati）获得营销学士学位，在肯塔基州默里州立大学（Murray State University）获得工商管理硕士学位。
- Shawn C. Tomasello,has served on the Board since June 2019.From 2015 to 2018, Ms. Tomasello as the Chief Commercial Officer of Kite Pharma. Prior to joining Kite Pharma, from 2014 to 2015, Ms. Tomasello served as the Chief Commercial Officer of Pharmacyclics Inc. (Nasdaq: PCYC), a pharmaceutical manufacturer acquired by Abbvie, Inc. (NYSE: ABBV). From April 2005 to August 2014, Ms. Tomasello was employed at Celgene Corporation, most recently as President of the Americas, Hematology and Oncology, where she was responsible for all aspects of the commercial organization encompassing multiple brands spanning 11 indications. Ms. Tomasello serves on the board of directors of Cabaletta Bio (Nasdaq: CABA), 4D Molecular Therapeutics (Nasdaq: FDMT) and AlloVir, Inc. (Nasdaq: ALVR). Ms. Tomasello earned her B.S. in Marketing from the University of Cincinnati and her M.B.A. from Murray State University, Kentucky.
- Stephen W. Webster
-
Stephen W. Webster 于 2020 年 5 月加入 Tcr2 Therapeutics Inc. 董事会，并于 2022 年 1 月成为 Tcr2 Therapeutics Inc. 董事长。Webster 先生自 7 月起担任上市基因治疗生物技术公司 Spark Therapeutics 的首席财务官2014 年至 2019 年 12 月被罗氏以 48 亿美元收购。从 2012 年 7 月至 2013 年 10 月被 Cubist Pharmaceuticals 收购，他曾担任上市生物技术公司 Optimer Pharmaceuticals 的高级副总裁兼首席财务官。加入 Optimer 后，Webster 先生从 2008 年到 2011 年被 Cubist Pharmaceuticals 收购，担任生物制药公司 Adolor Corporation 的高级副总裁兼首席财务官。Webster 先生还曾在 Broadpoint Capital 的投资银行医疗保健集团和PaineWebber 公司。 Webster 先生自 2019 年 4 月起担任 NextCure 的董事，自 2016 年 8 月起担任 Nabriva Therapeutics AG（前身为 Nabriva Therapeutics plc），自 2020 年起担任 Cullinan Oncology, Inc. 的董事。Webster 先生获得了 A.B.达特茅斯学院经济学学士学位和宾夕法尼亚大学沃顿商学院金融学工商管理硕士学位。
Stephen W. Webster joined Tcr2 Therapeutics Inc. Board of Directors in May 2020 and became Tcr2 Therapeutics Inc. Chairman in January of 2022. Mr. Webster served as the Chief Financial Officer of Spark Therapeutics, a publicly traded gene therapy biotechnology company, from July 2014 until its acquisition by Roche for $ 4.8 billion in December 2019. He was previously Senior Vice President SVP and Chief Financial Officer of Optimer Pharmaceuticals, a publicly traded biotechnology company, from July 2012 until its acquisition by Cubist Pharmaceuticals in October 2013. Prior to joining Optimer, Mr. Webster served as SVP and Chief Financial Officer of Adolor Corporation, a biopharmaceutical company, from 2008 until its acquisition by Cubist Pharmaceuticals in 2011. Mr. Webster also served in leadership positions in the investment banking healthcare groups of Broadpoint Capital and PaineWebber Incorporated. Mr. Webster has served as a director of NextCure since April 2019 Nabriva Therapeutics AG (formerly Nabriva Therapeutics plc) since August 2016 and Cullinan Oncology, Inc. since 2020. Mr. Webster received an A.B. in Economics from Dartmouth College and an M.B.A. in Finance from The Wharton School of the University of Pennsylvania. - Stephen W. Webster 于 2020 年 5 月加入 Tcr2 Therapeutics Inc. 董事会，并于 2022 年 1 月成为 Tcr2 Therapeutics Inc. 董事长。Webster 先生自 7 月起担任上市基因治疗生物技术公司 Spark Therapeutics 的首席财务官2014 年至 2019 年 12 月被罗氏以 48 亿美元收购。从 2012 年 7 月至 2013 年 10 月被 Cubist Pharmaceuticals 收购，他曾担任上市生物技术公司 Optimer Pharmaceuticals 的高级副总裁兼首席财务官。加入 Optimer 后，Webster 先生从 2008 年到 2011 年被 Cubist Pharmaceuticals 收购，担任生物制药公司 Adolor Corporation 的高级副总裁兼首席财务官。Webster 先生还曾在 Broadpoint Capital 的投资银行医疗保健集团和PaineWebber 公司。 Webster 先生自 2019 年 4 月起担任 NextCure 的董事，自 2016 年 8 月起担任 Nabriva Therapeutics AG（前身为 Nabriva Therapeutics plc），自 2020 年起担任 Cullinan Oncology, Inc. 的董事。Webster 先生获得了 A.B.达特茅斯学院经济学学士学位和宾夕法尼亚大学沃顿商学院金融学工商管理硕士学位。
- Stephen W. Webster joined Tcr2 Therapeutics Inc. Board of Directors in May 2020 and became Tcr2 Therapeutics Inc. Chairman in January of 2022. Mr. Webster served as the Chief Financial Officer of Spark Therapeutics, a publicly traded gene therapy biotechnology company, from July 2014 until its acquisition by Roche for $ 4.8 billion in December 2019. He was previously Senior Vice President SVP and Chief Financial Officer of Optimer Pharmaceuticals, a publicly traded biotechnology company, from July 2012 until its acquisition by Cubist Pharmaceuticals in October 2013. Prior to joining Optimer, Mr. Webster served as SVP and Chief Financial Officer of Adolor Corporation, a biopharmaceutical company, from 2008 until its acquisition by Cubist Pharmaceuticals in 2011. Mr. Webster also served in leadership positions in the investment banking healthcare groups of Broadpoint Capital and PaineWebber Incorporated. Mr. Webster has served as a director of NextCure since April 2019 Nabriva Therapeutics AG (formerly Nabriva Therapeutics plc) since August 2016 and Cullinan Oncology, Inc. since 2020. Mr. Webster received an A.B. in Economics from Dartmouth College and an M.B.A. in Finance from The Wharton School of the University of Pennsylvania.
- Ansbert Gadicke
-
Ansbert Gadicke 于 2015 年 5 月加入 Tcr2 Therapeutics Inc. 董事会。Gadicke 博士于 1997 年共同创立了 MPM Capital 的风险投资活动，此后一直担任董事总经理。 在此之前，Gadicke 博士于 1992 年至 1996 年领导 MPM Capital 的咨询和投资银行业务，并于 1989 年至 1992 年在Boston Consulting Group's Health Care Group的医疗保健集团工作。他是 Cullinan Oncology, LLC 和 ElevateBio 的董事会成员， LLC，曾任 Radius Health, Inc. 和 Chiasma, Inc. 的董事会成员。 Gadicke 博士从 J.W. 获得医学博士学位。 歌德大学，并曾在怀特黑德研究所和哈佛大学担任研究职位。
Ansbert Gadicke joined Tcr2 Therapeutics Inc. Board of Directors in May 2015. Dr. Gadicke co-founded MPM Capital's venture investing activities in 1997 and has since served as a Managing Director. Prior to that, Dr. Gadicke led MPM Capital's Advisory and Investment Banking business from 1992 to 1996 and was in Boston Consulting Group's Health Care Group from 1989 to 1992. He is a member of the board of directors of Cullinan Oncology, LLC and ElevateBio, LLC and formerly served as a member of the board of directors of Radius Health, Inc. and Chiasma, Inc. Dr. Gadicke received his M.D. from J.W. Goethe University and has held research positions at the Whitehead Institute and Harvard University. - Ansbert Gadicke 于 2015 年 5 月加入 Tcr2 Therapeutics Inc. 董事会。Gadicke 博士于 1997 年共同创立了 MPM Capital 的风险投资活动，此后一直担任董事总经理。 在此之前，Gadicke 博士于 1992 年至 1996 年领导 MPM Capital 的咨询和投资银行业务，并于 1989 年至 1992 年在Boston Consulting Group's Health Care Group的医疗保健集团工作。他是 Cullinan Oncology, LLC 和 ElevateBio 的董事会成员， LLC，曾任 Radius Health, Inc. 和 Chiasma, Inc. 的董事会成员。 Gadicke 博士从 J.W. 获得医学博士学位。 歌德大学，并曾在怀特黑德研究所和哈佛大学担任研究职位。
- Ansbert Gadicke joined Tcr2 Therapeutics Inc. Board of Directors in May 2015. Dr. Gadicke co-founded MPM Capital's venture investing activities in 1997 and has since served as a Managing Director. Prior to that, Dr. Gadicke led MPM Capital's Advisory and Investment Banking business from 1992 to 1996 and was in Boston Consulting Group's Health Care Group from 1989 to 1992. He is a member of the board of directors of Cullinan Oncology, LLC and ElevateBio, LLC and formerly served as a member of the board of directors of Radius Health, Inc. and Chiasma, Inc. Dr. Gadicke received his M.D. from J.W. Goethe University and has held research positions at the Whitehead Institute and Harvard University.
高管简历
中英对照 | 中文 | 英文- Alfonso Quintas Cardama
Alfonso Quintas Cardama于2017年加入我们公司，担任首席医疗官。Quint&225；s博士于2017年担任GlaxoSmithKline plc细胞和基因治疗部门的临床开发主管。2014年至2016年，他曾担任Novartis AG细胞和基因疗法全球临床负责人，并于2009年至2014年担任德克萨斯大学MD安德森癌症中心白血病部门助理教授。Quint&225；s博士在西班牙圣地亚哥大学（Universidad de Santiago de Compostela）医学院获得医学博士学位。他在the Albert Einstein College of Medicine-Yeshiva University的医学系完成实习和住院医师，在University of Texas，MD Anderson Cancer Center完成血液学和肿瘤学奖学金和白血病奖学金。
Alfonso Quintas Cardama joined Tcr2 Therapeutics Inc. company in 2017 as Chief Medical Officer. Dr. Quintás was the Clinical Development Head of the Cell & Gene Therapies Unit at GlaxoSmithKline PLC in 2017. Between 2014 and 2016 he served as Global Clinical Leader, Cell & Gene Therapy, at Novartis AG and was an Assistant Professor in the Department of Leukemia at The University of Texas, MD Anderson Cancer Center from 2009 to 2014. Dr. Quintás received his M.D. from the Universidad de Santiago de Compostela School of Medicine in Spain. He completed an internship and residency in the Department of Medicine of the Albert Einstein College of Medicine-Yeshiva University and a hematology and oncology fellowship and a leukemia fellowship at The University of Texas, MD Anderson Cancer Center.- Alfonso Quintas Cardama于2017年加入我们公司，担任首席医疗官。Quint&225；s博士于2017年担任GlaxoSmithKline plc细胞和基因治疗部门的临床开发主管。2014年至2016年，他曾担任Novartis AG细胞和基因疗法全球临床负责人，并于2009年至2014年担任德克萨斯大学MD安德森癌症中心白血病部门助理教授。Quint&225；s博士在西班牙圣地亚哥大学（Universidad de Santiago de Compostela）医学院获得医学博士学位。他在the Albert Einstein College of Medicine-Yeshiva University的医学系完成实习和住院医师，在University of Texas，MD Anderson Cancer Center完成血液学和肿瘤学奖学金和白血病奖学金。
- Alfonso Quintas Cardama joined Tcr2 Therapeutics Inc. company in 2017 as Chief Medical Officer. Dr. Quintás was the Clinical Development Head of the Cell & Gene Therapies Unit at GlaxoSmithKline PLC in 2017. Between 2014 and 2016 he served as Global Clinical Leader, Cell & Gene Therapy, at Novartis AG and was an Assistant Professor in the Department of Leukemia at The University of Texas, MD Anderson Cancer Center from 2009 to 2014. Dr. Quintás received his M.D. from the Universidad de Santiago de Compostela School of Medicine in Spain. He completed an internship and residency in the Department of Medicine of the Albert Einstein College of Medicine-Yeshiva University and a hematology and oncology fellowship and a leukemia fellowship at The University of Texas, MD Anderson Cancer Center.
- Garry Menzel
Garry Menzel于2016年加入我们公司，担任董事兼首席执行官。Menzel博士自2014年以来还担任肿瘤公司Black Diamond Therapeutics Inc.的董事会和审计委员会主席。此前，孟泽尔博士曾于2015年至2016年担任Axcella HealthInc.首席战略官，2013年至2015年担任达维塔梦百合Partners Inc.首席财务官，2008年至2013年担任Regulus TherapeuticsInc.首席运营官。Menzel博士还分别于1994年至2004年和2004年至2008年在高盛公司（Goldman Sachs&Co.LLC）和Credit Suisse Group Ag公司（McKinsey）担任生物技术实践的全球领导职务。此外，他还是贝恩咨询公司（Bain&Company）的顾问，也是SmithKline Beecham plc（现为GlaxoSmithKline plc）的研究助理。Menzel博士在剑桥大学（University of Cambridge）获得博士学位，在那里他研究免疫细胞中癌基因的调控，并在斯坦福大学商学院（Stanford University Graduate School of Business）获得工商管理硕士学位。
Garry Menzel joined Tcr2 Therapeutics Inc. company in 2016 as a director and Chief Executive Officer. Dr. Menzel has also served on the Board of Directors and chairman of the audit committee of the oncology company Black Diamond Therapeutics Inc. since 2014 and has served on the Board of Directors of Stoke Therapeutics Inc. since 2020. Previously, Dr. Menzel was the Chief Strategy Officer at Axcella Health Inc. from 2015 to 2016 the Chief Financial Officer at DaVita Healthcare Partners Inc. from 2013 to 2015 and the Chief Operating Officer at Regulus Therapeutics Inc. from 2008 to 2013. Dr. Menzel also had global leadership roles in running the biotechnology practices at Goldman Sachs & Co. LLC from 1994 to 2004 and Credit Suisse Group AG from 2004 to 2008. In addition, he was a consultant with Bain & Company and was a research assistant at SmithKline Beecham PLC now GlaxoSmithKline PLC. Dr. Menzel received his Ph.D. from the University of Cambridge, where he studied the regulation of oncogenes in immune cells, and his M.B.A. from the Stanford University Graduate School of Business.- Garry Menzel于2016年加入我们公司，担任董事兼首席执行官。Menzel博士自2014年以来还担任肿瘤公司Black Diamond Therapeutics Inc.的董事会和审计委员会主席。此前，孟泽尔博士曾于2015年至2016年担任Axcella HealthInc.首席战略官，2013年至2015年担任达维塔梦百合Partners Inc.首席财务官，2008年至2013年担任Regulus TherapeuticsInc.首席运营官。Menzel博士还分别于1994年至2004年和2004年至2008年在高盛公司（Goldman Sachs&Co.LLC）和Credit Suisse Group Ag公司（McKinsey）担任生物技术实践的全球领导职务。此外，他还是贝恩咨询公司（Bain&Company）的顾问，也是SmithKline Beecham plc（现为GlaxoSmithKline plc）的研究助理。Menzel博士在剑桥大学（University of Cambridge）获得博士学位，在那里他研究免疫细胞中癌基因的调控，并在斯坦福大学商学院（Stanford University Graduate School of Business）获得工商管理硕士学位。
- Garry Menzel joined Tcr2 Therapeutics Inc. company in 2016 as a director and Chief Executive Officer. Dr. Menzel has also served on the Board of Directors and chairman of the audit committee of the oncology company Black Diamond Therapeutics Inc. since 2014 and has served on the Board of Directors of Stoke Therapeutics Inc. since 2020. Previously, Dr. Menzel was the Chief Strategy Officer at Axcella Health Inc. from 2015 to 2016 the Chief Financial Officer at DaVita Healthcare Partners Inc. from 2013 to 2015 and the Chief Operating Officer at Regulus Therapeutics Inc. from 2008 to 2013. Dr. Menzel also had global leadership roles in running the biotechnology practices at Goldman Sachs & Co. LLC from 1994 to 2004 and Credit Suisse Group AG from 2004 to 2008. In addition, he was a consultant with Bain & Company and was a research assistant at SmithKline Beecham PLC now GlaxoSmithKline PLC. Dr. Menzel received his Ph.D. from the University of Cambridge, where he studied the regulation of oncogenes in immune cells, and his M.B.A. from the Stanford University Graduate School of Business.
- Angela Justice
Angela Justice于2019年10月加入我们公司，担任首席人力官。2018年3月至2019年7月，Justice博士担任SurgeryPartners，Inc.首席人力资源官2012年至2018年2月，Justice博士在Biogen，Inc.担任过多个职位，包括2015年4月至2018年2月担任首席学习官，2012年至2015年担任Biogen全球医疗事务高级总监。Justice博士在明尼苏达州立大学曼卡托分校（Minnesota State University at Mankato）获得学士学位，在芝加哥大学（University of Chicago）获得博士学位。
Angela Justice joined Tcr2 Therapeutics Inc. company in October 2019 as Chief People Officer. From March 2018 to July 2019 Dr. Justice was the Chief Human Resources Officer at Surgery Partners, Inc. From 2012 to February 2018 Dr. Justice held several positions at Biogen, Inc., including serving as Chief Learning Officer from April 2015 to February 2018 and Senior Director of Global Medical Affairs for Biogen from 2012 to 2015. Dr. Justice received her B.S. from Minnesota State University at Mankato and her Ph.D. from the University of Chicago.- Angela Justice于2019年10月加入我们公司，担任首席人力官。2018年3月至2019年7月，Justice博士担任SurgeryPartners，Inc.首席人力资源官2012年至2018年2月，Justice博士在Biogen，Inc.担任过多个职位，包括2015年4月至2018年2月担任首席学习官，2012年至2015年担任Biogen全球医疗事务高级总监。Justice博士在明尼苏达州立大学曼卡托分校（Minnesota State University at Mankato）获得学士学位，在芝加哥大学（University of Chicago）获得博士学位。
- Angela Justice joined Tcr2 Therapeutics Inc. company in October 2019 as Chief People Officer. From March 2018 to July 2019 Dr. Justice was the Chief Human Resources Officer at Surgery Partners, Inc. From 2012 to February 2018 Dr. Justice held several positions at Biogen, Inc., including serving as Chief Learning Officer from April 2015 to February 2018 and Senior Director of Global Medical Affairs for Biogen from 2012 to 2015. Dr. Justice received her B.S. from Minnesota State University at Mankato and her Ph.D. from the University of Chicago.
- Peter Olagunju
Peter Olagunju于2021年7月加入我们公司担任首席技术官。Olagunju从2020年3月到2021年7月担任Fergene Inc.技术运营高级副总裁。从2015年到2020年3月，Olagunju先生在bluebirdbio，Inc.担任多个职位，包括担任全球患者运营副总裁，并担任项目负责人和支持Zynteglo®；欧洲批准的制造职能主管。2015年之前，他曾担任商业技术运营高级职位，并担任Dendreon Corp.和ZymoGenetics，Inc.的质量主管。Olagunju先生拥有华盛顿大学的工商管理硕士学位和伊利诺伊大学香槟分校的生物学学士学位。
Peter Olagunju joined Tcr2 Therapeutics Inc. company in July 2021 as Chief Technical Officer. He brings over 20 years of experience in cell and gene therapy, clinical development, program management, manufacturing and technical operations. Prior to joining Tcr2 Therapeutics Inc. company, from March 2020 to July 2021 Mr. Olagunju was Senior Vice President of Technical Operations at FerGene Inc., where he led the technical operations function for the commercialization of a gene therapy for bladder cancer. Before that, from 2015 to March 2020 Mr. Olagunju held several roles of increasing responsibility at bluebird bio, Inc., including serving serving as Vice President of Global Patient Operations where he was the program lead and functional head of manufacturing supporting the European approval for ZYNTEGLO®, a transformational gene therapy for Transfusion dependent Thalassemia. Earlier in his career, he held senior positions in Commercial Technical Operations and served as the Head of Quality at Dendreon Corp. and ZymoGenetics, Inc. Mr. Olagunju holds an M.B.A. from the University of Washington and a B.S. in Biology from the University of Illinois at Urbana-Champaign.- Peter Olagunju于2021年7月加入我们公司担任首席技术官。Olagunju从2020年3月到2021年7月担任Fergene Inc.技术运营高级副总裁。从2015年到2020年3月，Olagunju先生在bluebirdbio，Inc.担任多个职位，包括担任全球患者运营副总裁，并担任项目负责人和支持Zynteglo®；欧洲批准的制造职能主管。2015年之前，他曾担任商业技术运营高级职位，并担任Dendreon Corp.和ZymoGenetics，Inc.的质量主管。Olagunju先生拥有华盛顿大学的工商管理硕士学位和伊利诺伊大学香槟分校的生物学学士学位。
- Peter Olagunju joined Tcr2 Therapeutics Inc. company in July 2021 as Chief Technical Officer. He brings over 20 years of experience in cell and gene therapy, clinical development, program management, manufacturing and technical operations. Prior to joining Tcr2 Therapeutics Inc. company, from March 2020 to July 2021 Mr. Olagunju was Senior Vice President of Technical Operations at FerGene Inc., where he led the technical operations function for the commercialization of a gene therapy for bladder cancer. Before that, from 2015 to March 2020 Mr. Olagunju held several roles of increasing responsibility at bluebird bio, Inc., including serving serving as Vice President of Global Patient Operations where he was the program lead and functional head of manufacturing supporting the European approval for ZYNTEGLO®, a transformational gene therapy for Transfusion dependent Thalassemia. Earlier in his career, he held senior positions in Commercial Technical Operations and served as the Head of Quality at Dendreon Corp. and ZymoGenetics, Inc. Mr. Olagunju holds an M.B.A. from the University of Washington and a B.S. in Biology from the University of Illinois at Urbana-Champaign.
- Rosemary Harrison
Rosemary Harrison于2022年1月加入Tcr2 Therapeutics公司，担任首席业务和战略官。她在制药和生物技术公司的战略规划、投资组合管理和业务发展方面拥有近20年的全球经验。在加入公司之前，她于2020年10月至2021年11月担任副总裁0的企业发展和战略高级副总裁，并于2021年11月领导延龄草治疗以22.2亿美元收购该公司。在此之前，Harrison博士于2018年6月至2019年6月在RA Capital Management担任战略和研究职务，2019年6月至2020年3月担任Imbria Pharmaceuticals罕见病主管，并担任投资组合管理主管2015年3月至2018年5月在诺华生物医学研究所进行战略规划。在她职业生涯的早期，Harrison博士曾在贝恩公司担任顾问，为公司战略和运营计划提供建议。Harrison博士拥有药物设计和开发生物技术学士学位和博士学位。来自昆士兰大学。
Rosemary Harrison joined Tcr2 Therapeutics Inc. company in January 2022 as Chief Business and Strategy Officer. She brings nearly 20 years of global experience working on strategic planning, portfolio management and business development at both pharmaceutical and biotechnology companies. Prior to joining the Company, she was Senior Vice President of Corporate Development and Strategy at Trillium Therapeutics from October 2020 to November 2021 where she led its acquisition by Pfizer for $2.22 billion in November 2021. Before that, Dr. Harrison served in strategic and research roles within RA Capital Management from June 2018 to June 2019 as Head of Rare Diseases at Imbria Pharmaceuticals from June 2019 to March 2020 and as Head of Portfolio Management and Strategic Planning at the Novartis Institutes for Biomedical Research from March 2015 to May 2018. Earlier in her career, Dr Harrison served as a consultant at Bain & Company where she advised on corporate strategic and operational programs. Dr. Harrison holds a Bachelor of Biotechnology in Drug Design and Development and a Ph.D. from The University of Queensland.- Rosemary Harrison于2022年1月加入Tcr2 Therapeutics公司，担任首席业务和战略官。她在制药和生物技术公司的战略规划、投资组合管理和业务发展方面拥有近20年的全球经验。在加入公司之前，她于2020年10月至2021年11月担任副总裁0的企业发展和战略高级副总裁，并于2021年11月领导延龄草治疗以22.2亿美元收购该公司。在此之前，Harrison博士于2018年6月至2019年6月在RA Capital Management担任战略和研究职务，2019年6月至2020年3月担任Imbria Pharmaceuticals罕见病主管，并担任投资组合管理主管2015年3月至2018年5月在诺华生物医学研究所进行战略规划。在她职业生涯的早期，Harrison博士曾在贝恩公司担任顾问，为公司战略和运营计划提供建议。Harrison博士拥有药物设计和开发生物技术学士学位和博士学位。来自昆士兰大学。
- Rosemary Harrison joined Tcr2 Therapeutics Inc. company in January 2022 as Chief Business and Strategy Officer. She brings nearly 20 years of global experience working on strategic planning, portfolio management and business development at both pharmaceutical and biotechnology companies. Prior to joining the Company, she was Senior Vice President of Corporate Development and Strategy at Trillium Therapeutics from October 2020 to November 2021 where she led its acquisition by Pfizer for $2.22 billion in November 2021. Before that, Dr. Harrison served in strategic and research roles within RA Capital Management from June 2018 to June 2019 as Head of Rare Diseases at Imbria Pharmaceuticals from June 2019 to March 2020 and as Head of Portfolio Management and Strategic Planning at the Novartis Institutes for Biomedical Research from March 2015 to May 2018. Earlier in her career, Dr Harrison served as a consultant at Bain & Company where she advised on corporate strategic and operational programs. Dr. Harrison holds a Bachelor of Biotechnology in Drug Design and Development and a Ph.D. from The University of Queensland.
- Stephen W. Webster
Stephen W. Webster 于 2020 年 5 月加入 Tcr2 Therapeutics Inc. 董事会，并于 2022 年 1 月成为 Tcr2 Therapeutics Inc. 董事长。Webster 先生自 7 月起担任上市基因治疗生物技术公司 Spark Therapeutics 的首席财务官2014 年至 2019 年 12 月被罗氏以 48 亿美元收购。从 2012 年 7 月至 2013 年 10 月被 Cubist Pharmaceuticals 收购，他曾担任上市生物技术公司 Optimer Pharmaceuticals 的高级副总裁兼首席财务官。加入 Optimer 后，Webster 先生从 2008 年到 2011 年被 Cubist Pharmaceuticals 收购，担任生物制药公司 Adolor Corporation 的高级副总裁兼首席财务官。Webster 先生还曾在 Broadpoint Capital 的投资银行医疗保健集团和PaineWebber 公司。 Webster 先生自 2019 年 4 月起担任 NextCure 的董事，自 2016 年 8 月起担任 Nabriva Therapeutics AG（前身为 Nabriva Therapeutics plc），自 2020 年起担任 Cullinan Oncology, Inc. 的董事。Webster 先生获得了 A.B.达特茅斯学院经济学学士学位和宾夕法尼亚大学沃顿商学院金融学工商管理硕士学位。
Stephen W. Webster joined Tcr2 Therapeutics Inc. Board of Directors in May 2020 and became Tcr2 Therapeutics Inc. Chairman in January of 2022. Mr. Webster served as the Chief Financial Officer of Spark Therapeutics, a publicly traded gene therapy biotechnology company, from July 2014 until its acquisition by Roche for $ 4.8 billion in December 2019. He was previously Senior Vice President SVP and Chief Financial Officer of Optimer Pharmaceuticals, a publicly traded biotechnology company, from July 2012 until its acquisition by Cubist Pharmaceuticals in October 2013. Prior to joining Optimer, Mr. Webster served as SVP and Chief Financial Officer of Adolor Corporation, a biopharmaceutical company, from 2008 until its acquisition by Cubist Pharmaceuticals in 2011. Mr. Webster also served in leadership positions in the investment banking healthcare groups of Broadpoint Capital and PaineWebber Incorporated. Mr. Webster has served as a director of NextCure since April 2019 Nabriva Therapeutics AG (formerly Nabriva Therapeutics plc) since August 2016 and Cullinan Oncology, Inc. since 2020. Mr. Webster received an A.B. in Economics from Dartmouth College and an M.B.A. in Finance from The Wharton School of the University of Pennsylvania.- Stephen W. Webster 于 2020 年 5 月加入 Tcr2 Therapeutics Inc. 董事会，并于 2022 年 1 月成为 Tcr2 Therapeutics Inc. 董事长。Webster 先生自 7 月起担任上市基因治疗生物技术公司 Spark Therapeutics 的首席财务官2014 年至 2019 年 12 月被罗氏以 48 亿美元收购。从 2012 年 7 月至 2013 年 10 月被 Cubist Pharmaceuticals 收购，他曾担任上市生物技术公司 Optimer Pharmaceuticals 的高级副总裁兼首席财务官。加入 Optimer 后，Webster 先生从 2008 年到 2011 年被 Cubist Pharmaceuticals 收购，担任生物制药公司 Adolor Corporation 的高级副总裁兼首席财务官。Webster 先生还曾在 Broadpoint Capital 的投资银行医疗保健集团和PaineWebber 公司。 Webster 先生自 2019 年 4 月起担任 NextCure 的董事，自 2016 年 8 月起担任 Nabriva Therapeutics AG（前身为 Nabriva Therapeutics plc），自 2020 年起担任 Cullinan Oncology, Inc. 的董事。Webster 先生获得了 A.B.达特茅斯学院经济学学士学位和宾夕法尼亚大学沃顿商学院金融学工商管理硕士学位。
- Stephen W. Webster joined Tcr2 Therapeutics Inc. Board of Directors in May 2020 and became Tcr2 Therapeutics Inc. Chairman in January of 2022. Mr. Webster served as the Chief Financial Officer of Spark Therapeutics, a publicly traded gene therapy biotechnology company, from July 2014 until its acquisition by Roche for $ 4.8 billion in December 2019. He was previously Senior Vice President SVP and Chief Financial Officer of Optimer Pharmaceuticals, a publicly traded biotechnology company, from July 2012 until its acquisition by Cubist Pharmaceuticals in October 2013. Prior to joining Optimer, Mr. Webster served as SVP and Chief Financial Officer of Adolor Corporation, a biopharmaceutical company, from 2008 until its acquisition by Cubist Pharmaceuticals in 2011. Mr. Webster also served in leadership positions in the investment banking healthcare groups of Broadpoint Capital and PaineWebber Incorporated. Mr. Webster has served as a director of NextCure since April 2019 Nabriva Therapeutics AG (formerly Nabriva Therapeutics plc) since August 2016 and Cullinan Oncology, Inc. since 2020. Mr. Webster received an A.B. in Economics from Dartmouth College and an M.B.A. in Finance from The Wharton School of the University of Pennsylvania.
- Eric Sullivan
Eric Sullivan 于 2022 年加入 Tcr2 Therapeutics Inc. 公司，担任首席财务官。 在加入Tcr2 Therapeutics Inc. 之前，Sullivan 先生于 2019 年至 2021 年担任 Triplet Therapeutics 的总裁、首席财务官和首席运营官，负责领导财务、业务发展和企业运营。 在此之前，Sullivan 先生在 2017 年至 2019 年期间担任 Gemini Therapeutics 和 Oncorus 的高级副总裁领导财务。 在他职业生涯的早期，他曾在 bluebird bio 和 Merrimack Pharmaceuticals 担任高级财务管理职位。 Sullivan 先生拥有学士学位。 在本特利大学获得会计学学士学位，并且是注册会计师 CPA。
Eric Sullivan joined Tcr2 Therapeutics Inc. company in 2022 as Chief Financial Officer. Prior to joining the Company, Mr. Sullivan was President, Chief Financial Officer and Chief Operating Officer at Triplet Therapeutics from 2019 to 2021 where he led finance, business development and corporate operations. Before that, between 2017 and 2019 Mr. Sullivan led finance as Senior Vice President at Gemini Therapeutics and Oncorus. Earlier in his career, he held senior financial management positions at bluebird bio and Merrimack Pharmaceuticals. Mr. Sullivan holds a B.S. in Accountancy from Bentley University and is a Certified Public Accountant CPA.- Eric Sullivan 于 2022 年加入 Tcr2 Therapeutics Inc. 公司，担任首席财务官。 在加入Tcr2 Therapeutics Inc. 之前，Sullivan 先生于 2019 年至 2021 年担任 Triplet Therapeutics 的总裁、首席财务官和首席运营官，负责领导财务、业务发展和企业运营。 在此之前，Sullivan 先生在 2017 年至 2019 年期间担任 Gemini Therapeutics 和 Oncorus 的高级副总裁领导财务。 在他职业生涯的早期，他曾在 bluebird bio 和 Merrimack Pharmaceuticals 担任高级财务管理职位。 Sullivan 先生拥有学士学位。 在本特利大学获得会计学学士学位，并且是注册会计师 CPA。
- Eric Sullivan joined Tcr2 Therapeutics Inc. company in 2022 as Chief Financial Officer. Prior to joining the Company, Mr. Sullivan was President, Chief Financial Officer and Chief Operating Officer at Triplet Therapeutics from 2019 to 2021 where he led finance, business development and corporate operations. Before that, between 2017 and 2019 Mr. Sullivan led finance as Senior Vice President at Gemini Therapeutics and Oncorus. Earlier in his career, he held senior financial management positions at bluebird bio and Merrimack Pharmaceuticals. Mr. Sullivan holds a B.S. in Accountancy from Bentley University and is a Certified Public Accountant CPA.